Suppr超能文献

优化硫嘌呤类药物在炎症性肠病中的应用

Optimizing the use of thiopurines in inflammatory bowel disease.

作者信息

Goel Rishi M, Blaker Paul, Mentzer Alex, Fong Steven C M, Marinaki Anthony M, Sanderson Jeremy D

机构信息

Guy's & St Thomas' Hospitals - Gastroenterology, Westminster Bridge Road, London SE1 7EH, UK.

Guy's & St Thomas' Hospitals - Gastroenterology, London, UK.

出版信息

Ther Adv Chronic Dis. 2015 May;6(3):138-46. doi: 10.1177/2040622315579063.

Abstract

Immunomodulator drugs, of which thiopurines can be considered the backbone, are widely used in the treatment of inflammatory bowel disease. They have been shown to be highly effective and safe; however, a significant proportion of patients are deemed to have a poor response or suffer adverse reactions. Knowing how to monitor and optimize thiopurine therapy in these scenarios is crucial to effective management. We discuss the metabolism of thiopurines, the use of enzyme/metabolite testing to guide treatment, as well as strategies to circumvent toxicity and side effects, such as allopurinol coprescription. The indications, use in pregnancy, safety profile and duration of thiopurine therapy are also discussed.

摘要

免疫调节药物,其中硫嘌呤类药物可被视为基础药物,广泛用于治疗炎症性肠病。这些药物已被证明具有高效性和安全性;然而,相当一部分患者被认为反应不佳或出现不良反应。了解在这些情况下如何监测和优化硫嘌呤治疗对于有效管理至关重要。我们讨论了硫嘌呤的代谢、使用酶/代谢物检测来指导治疗,以及规避毒性和副作用的策略,如联合使用别嘌醇。还讨论了硫嘌呤治疗的适应症、孕期使用情况、安全性概况和疗程。

相似文献

1
Optimizing the use of thiopurines in inflammatory bowel disease.
Ther Adv Chronic Dis. 2015 May;6(3):138-46. doi: 10.1177/2040622315579063.
2
The drug-survival of low-dose thioguanine in patients with inflammatory bowel disease: a retrospective observational study.
Therap Adv Gastroenterol. 2024 Feb 20;17:17562848241228064. doi: 10.1177/17562848241228064. eCollection 2024.
3
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease.
Gastroenterol Hepatol. 2018 Mar;41(3):205-221. doi: 10.1016/j.gastrohep.2017.11.007. Epub 2018 Jan 19.
4
Outcome of concomitant treatment with thiopurines and allopurinol in patients with inflammatory bowel disease: A nationwide Danish cohort study.
United European Gastroenterol J. 2020 Feb;8(1):68-76. doi: 10.1177/2050640619868387. Epub 2019 Aug 3.
5
Use of thiopurines in inflammatory bowel disease.
World J Gastroenterol. 2013 Feb 21;19(7):1040-8. doi: 10.3748/wjg.v19.i7.1040.
6
Thiopurine therapy in inflammatory bowel disease.
Expert Rev Gastroenterol Hepatol. 2010 Oct;4(5):575-88. doi: 10.1586/egh.10.59.
7
Addition of Allopurinol for Altering Thiopurine Metabolism to Optimize Therapy in Patients with Inflammatory Bowel Disease.
Pharmacotherapy. 2018 Feb;38(2):259-270. doi: 10.1002/phar.2067. Epub 2018 Jan 10.
8
Optimising use of thiopurines in inflammatory bowel disease.
Expert Rev Clin Immunol. 2017 Sep;13(9):877-888. doi: 10.1080/1744666X.2017.1351298. Epub 2017 Jul 12.
9
Relapse rates after withdrawal of thiopurines in patients with inflammatory bowel disease.
Int J Colorectal Dis. 2022 Aug;37(8):1817-1826. doi: 10.1007/s00384-022-04216-5. Epub 2022 Jul 14.
10
Thiopurines in Inflammatory Bowel Disease. How to Optimize Thiopurines in the Biologic Era?
Front Med (Lausanne). 2021 Jul 16;8:681907. doi: 10.3389/fmed.2021.681907. eCollection 2021.

引用本文的文献

1
Clinical Actionability of the NUDT15 *4 (p.R139H) Allele and Its Association With Hispanic Ethnicity.
Clin Pharmacol Ther. 2025 Mar;117(3):724-731. doi: 10.1002/cpt.3501. Epub 2024 Dec 17.
3
Clinician's Guide to Using Ozanimod for the Treatment of Ulcerative Colitis.
J Crohns Colitis. 2023 Dec 30;17(12):2012-2025. doi: 10.1093/ecco-jcc/jjad112.
5
Biomarkers for gastrointestinal adverse events related to thiopurine therapy.
World J Gastroenterol. 2021 Oct 14;27(38):6348-6356. doi: 10.3748/wjg.v27.i38.6348.
7
Thiopurines in Inflammatory Bowel Disease. How to Optimize Thiopurines in the Biologic Era?
Front Med (Lausanne). 2021 Jul 16;8:681907. doi: 10.3389/fmed.2021.681907. eCollection 2021.
8
Use of thiopurines in inflammatory bowel disease: an update.
Intest Res. 2022 Jan;20(1):11-30. doi: 10.5217/ir.2020.00155. Epub 2021 Apr 15.
10
Evolving Role of Thiopurines in Inflammatory Bowel Disease in the Era of Biologics and New Small Molecules.
Dig Dis Sci. 2021 Oct;66(10):3250-3262. doi: 10.1007/s10620-020-06662-z. Epub 2020 Oct 19.

本文引用的文献

1
The pharmacogenetic basis of individual variation in thiopurine metabolism.
Per Med. 2012 Sep;9(7):707-725. doi: 10.2217/pme.12.85.
2
6
Are we using and monitoring thiopurines and biologics optimally?
Dig Dis. 2014;32(4):410-8. doi: 10.1159/000358147. Epub 2014 Jun 23.
7
Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
Pharmacoepidemiol Drug Saf. 2014 Jul;23(7):735-44. doi: 10.1002/pds.3621. Epub 2014 Apr 30.
8
Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease.
Clin Gastroenterol Hepatol. 2014 Aug;12(8):1324-9. doi: 10.1016/j.cgh.2014.02.026. Epub 2014 Feb 26.
9
The role of thiopurines in reducing the need for surgical resection in Crohn's disease: a systematic review and meta-analysis.
Am J Gastroenterol. 2014 Jan;109(1):23-34; quiz 35. doi: 10.1038/ajg.2013.402. Epub 2013 Dec 10.
10
Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy.
Aliment Pharmacol Ther. 2013 Nov;38(9):1025-37. doi: 10.1111/apt.12490. Epub 2013 Sep 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验